NCT06597630 Pathological Type，Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism
| NCT ID | NCT06597630 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qifu Li |
| Condition | Primary Aldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2024-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-12-01 with a primary completion date of 2024-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Aim to investigate the pathological feature of UPA in Asians 2. To clarify the relationship between pathology, clinical phenotype, genetic mutation and surgical outcome of UPA in Asians. 3. To explore a new pathological type of unilateral primary aldosterone
Eligibility Criteria
Inclusion Criteria: 1. No gender limitation; 2. Age 18-80 years old; 3. The patient was diagnosed with UPA and underwent total adrenal resection. Exclusion Criteria: 1. Bilateral disease 2. Partial of no biochemical response in follow-up 3. partial adrenalectomy
Contact & Investigator
Li Qifu
STUDY CHAIR
First Affiliated Hospital of Chongqing Medical University
Frequently Asked Questions
Who can join the NCT06597630 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06597630 currently recruiting?
Yes, NCT06597630 is actively recruiting participants. Contact the research team at liqifu@yeah.net for enrollment information.
Where is the NCT06597630 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06597630 clinical trial?
NCT06597630 is sponsored by Qifu Li. The principal investigator is Li Qifu at First Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 100 participants.